patients. A personal history of Reiter's syndrome was noted in 2.22% of patients and of uveitis in 6.66%. Morning stiffness was noted in 60% (n=27) of patients. Good response to nonsteroidal anti-inflammatory drugs (NSAIDs) and to physical activity were respectively reported by 42.22% (n=19) and 57.8% (n=26) of patients. Twenty-seven per cent of the patients were HLA-B27+. Fifty-one per cent of the studied patients fulfilled the ASAS criteria for axial SpA and 46.7% fulfilled the Amor criteria. After a follow-up between 2 and 3 years, the diagnosis of SpA was confirmed by the referring rheumatologists in 31 (68.9%) patients and excluded in 14 (31.1%) patients. Among the 31 patients with confirmed SpA, 61.3% (n=19) had a positive US (with a mean RI estimated at 0.75) and 38.7% (n=12) had a normal US. Among the 14 patients in whom SpA was excluded, 50% (n=7) had a positive US (with a mean RI estimated at 0.7) and 50% had a normal US. Sensitivity and specificity of US examination were estimated at 61.3% and 50%. Positive and negative likelihood ratio were estimated at 73% and 36.8%. Association between US findings and rheumatologists' diagnosis of SpA was not statistically significant (p=0.47).

**Conclusion:** US contribution in the diagnostic of SpA has been little-studied. In our study, although US of SIJ lacked specificity, it has a satisfactory sensitivity and positive likehood ratio. In fact, this tool is more valuable by its positivity which indicates a high probability of sacroiliitis. However, further investigation is needed in order to assess its performance for ascertaining sacroiliitis.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.6346

AB0723

## SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA

Orhan Küçükşahin[1], Abdulsamet Erden[2], Ufuk İlgen[3], Sedat Kiraz[2], Ali İhsan Ertenli[2], Nazife Sule Yasar Bilge[4], Timuçin Kaşifoğlu[4],Ediz Dalkılıç[5], Cemal Bes[6], Nilüfer Alpay Kanıtez[7], Hakan Emmungil[3], Pamir Atagündüz[8,9],Belkis Nihan Seniz[5], Burcu Yağız[5], Süleyman Serdar Koca[10], Muhammet Çınar[11], Aşkın Ateş[12], Servet Akar[13],Önay Gerçik[13], Duygu Ersözlü[14], Veli Yazısız[15], Gezmiş Kimyon[16], Müge Aydın[17], Rıdvan Mercan[18], Burak Öz[10], Zeynel Abidin Akar[10], Omer Karadag[2], Bahar Keleşoğlu[12],Sedat Yılmaz[11], Yavuz Pehlivan[5], Ender Terzioğlu[15], Levent Kılıç[2], Sukran Erten[19], Koray Taşçılar[20], Umut Kalyoncu[2]. *[1]Ankara Liv Hospital, Rheumatology, Ankara, Turkey*; *[2]Hacettepe University Faculty of Medicine, Rheumatology, Ankara, Turkey*; *[3]Trakya University Faculty of Medicine, Rheumatology, Edirne, Turkey*; *[4]Eskisehir Osmangazi University Medical Faculty, Rheumatology, Eskişehir, Turkey*; *[5]Uludag University Faculty of Medicine, Rheumatology, Bursa, Turkey*; *[6]University of Health Sciences Bakırköy Sadi Konu education and research hospital, Rheumatology, İstanbul, Turkey*; *[7]Koç University, Rheumatology, İstanbul, Turkey*; *[8]Marmara University, Rheumatology, İstanbul, Turkey*; *[9]Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey*; *[10]Fırat University Faculty of Medicine, Rheumatology, Elazığ, Turkey*; *[11]University of Health Sciences Gülhane Training and Research Hospital, Rheumatology, Ankara, Turkey*; *[12]Ankara University Faculty of Medicine, Rheumatology, ankara, Turkey*; *[13]Katip Çelebi University Faculty of Medicine, Rheumatology, İzmir, Turkey*; *[14]Adana State Hospital, Rheumatology, Adana, Turkey*; *[15]Akdeniz University Faculty of Medicine, Rheumatology, Antalya, Turkey*; *[16]Mustafa Kemal University faculty of Medicine, Rheumatology, Hatay, Turkey*; *[17]Başkent University Faculty of Medicine, Rheumatology, Adana, Turkey*; *[18]Namık Kemal University Faculty of Medicine, Rheumatology, Tekirdağ, Turkey*; *[19]Yıldırım Beyazıt University Faculty of Medicine, Rheumatology, Ankara, Turkey*; *[20]Okmeydanı research and educational Hospital, Rheumatology, istanbul, Turkey*

**Background:** Articular manifestations may differ in ulcerative colitis (UC) and Crohn's disease (CD). Genetic and non-genetic factors like sex, smoking, and presence of HLA-B27 were previously shown to modify the expression of articular and other extraintestinal manifestations of IBD.

**Objectives:** The aim of this study is to document disease features and factors affecting the expression of articular manifestations in Turkish patients with IBD-related (enteropathic) arthritis under treatment with disease modifying antirheumatic drugs (DMARDs).

**Methods:** Data regarding enteropathic arthritis (EA) were collected from the TReasure database, a nation-wide multicenter observational registry of inflammatory arthritis patients.

**Table 1.** Demographic and clinical features of enteropathic arthritis patients with respect to inflammatory bowel disease form

| | N | Sacroiliitis (-) (n=18) | Sacroiliitis (+) (n=138) | p |
|---|---|---|---|---|
| Female, n (%) | 156 | 11 (61.1) | 55 (39.9) | 0.086 |
| Age, years (Q1-Q3) | 156 | 44 (31-58) | 46 (38-51) | 0.754 |
| EA duration, months (Q1-Q3) | 156 | 61 (24-146)* | 85 (36-146)* | 0.385 |
| Syndesmophytes, n (%) | 115 | 0 (0) | 28 (27.2) | **0.037** |
| Enthesitis, n (%) | 110 | 6 (50) | 31 (31.6) | 0.214 |
| Dactylitis, n (%) | 128 | 0 (0) | 3 (2.6) | Ns |
| Psoriasis, n (%) | 153 | 1 (5.6) | 5 (3.7) | Ns |
| Family history of SpA, n (%) | 118 | 2 (22.2) | 32 (29.4) | 1 |
| HLA-B27 positivity, n (%) | 90 | 1 (7.1) | 24 (31.6) | 0.1 |
| Smoking, n (%) | 146 | 6 (35.3) | 80 (62) | **0.035** |
| ESR, mm/h, (Q1-Q3) | 106 | 46 (14-74) | 37 (21-52) | 0.442 |
| CRP, mg/L, (Q1-Q3) | 106 | 29 (11.8-55.3) | 16.1 (8.12-38.1) | 0.367 |
| BASDAI, (Q1-Q3)# | 100 | 5.8 (4.5-8) | 5.6 (3.9-7) | 0.597 |
| BASFI, (Q1-Q3)# | 87 | 3.4 (2-6.1) | 3.2 (2-5) | 0.886 |
| ASDAS-ESR, (Q1-Q3)# | 72 | 3.25 (2.46-4.12) | 3.4 (2.59-3.91) | 0.948 |
| ASDAS-CRP, (Q1-Q3)# | 73 | 3.85 (2.72-4.73) | 3.53 (2.63-4.09) | 0.446 |

**Results:** Among 4066 patients with seronegative spondyloarthropaties (SpA), 156 (3.8%) had EA, not reflecting a true prevalence due to selection bias. Demographic and clinical features according to IBD groups were summarized in Table 1. Rates of presence of sacroiliitis were similar between patients with UC and CD (39.9% and 60.1%, p=0.086 respectively). Rates of HLA-B27 positivity were 31.6% and 7.1% in patients with and without radiographic sacroiliitis, respectively (p=0.101). Enthesitis, dactylitis, psoriasis, family history forSpA, ESR, CRP, BASDAI and ASDAS levels had similar distributions in patients with and without radiographic sacroiliitis. Rates of "never-smoked" (26.5% vs 64.7%) and "current smoking" (32.4% vs 17.6%) significantly differed in patients with and without sacroiliitis (overall p=0.012)

**Conclusion:** Our data confirm an association between smoking status and disease manifestations, particularly radiographic sacroiliitis.

## REFERENCES

[1] Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009; 15: 2449-2455.

**Disclosure of Interests:** Orhan Küçükşahin: None declared, Abdulsamet Erden: None declared, Ufuk İlgen: None declared, Sedat Kiraz: None declared, Ali İhsan Ertenli: None declared, Nazife Sule Yasar Bilge: None declared, Timuçin Kaşifoğlu: None declared, Ediz Dalkılıç Grant/research support from: MSD and Abbvie, Consultant for: MSD, Abbvie,Roche, UCB, Pfizer and Novartis, Speakers bureau: MSD, Abbvie,Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilüfer Alpay Kanıtez: None declared, Hakan Emmungil Grant/research support from: MSD, Roche, Pfizer, Abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, Abbvie,Celltrion, Novartis, Pamir Atagündüz: None declared, Belkis Nihan Seniz: None declared, Burcu Yağız: None declared, Süleyman Serdar Koca: None declared, Muhammet Çınar: None declared, Aşkın Ateş: None declared, Servet Akar Grant/research support from: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Speakers bureau: Pfizer, Önay Gerçik: None declared, Duygu Ersözlü: None declared, Veli yazısız: None declared, Gezmiş Kimyon: None declared, Müge Aydın: None declared, Rıdvan Mercan: None declared, Burak Öz: None declared, Zeynel Abidin Akar: None declared, Omer Karadag: None

Ann Rheum Dis: first published as 10.1136/annrheumdis-2019-eular.5888 on 27 June 2019. Downloaded from http://ard.bmj.com/ on November 27, 2020 at Eskisehir Osmangazi University. Protected by copyright.

declared, Bahar Keleşoğlu: None declared, Sedat Yılmaz: None declared, Yavuz Pehlivan: None declared, Ender Terzioğlu: None declared, Levent Kılıç: None declared, Sukran Erten: None declared, Koray Taşçılar: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim

**DOI:** 10.1136/annrheumdis-2019-eular.5888

## AB0724 DOSE PREGNANCY AND VAGINAL DELIVERY WORSEN ANKYLOSING SPONDYLITIS?

Jung Sun Lee[1], Ji Seon Oh[1], Wook Jang Seo[2], Seokchan Hong[1], Yong-Gil Kim[1], Chang-Keun Lee[1], Bin Yoo[1]. *[1]University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Rep. of (South Korea); [2]Veterans Health Service Medical Center, Seoul, Korea, Rep. of (South Korea)*

**Background** Ankylosing spondylitis (AS) affects the sacroiliac joints and commonly occurs in those at the reproductive age. Women with AS have a higher rate of cesarean section (CS) compared with healthy controls.
**Objectives** This study determined the effect of pregnancy and delivery methods on AS worsening by analyzing prescription pattern.
**Methods** Based on the Korean Health Insurance Review and Assessment Service claims database, subjects comprised female patients aged 20–49 years with an AS. Alteration of prescriptions was defined by changing the at two time periods of 1–2 years pre-delivery and 1-year post-delivery. We compared alteration of prescriptions between AS patients with delivery and 1:1 matched AS patients without delivery. In addition, among AS patients with delivery, alteration of prescriptions according to delivery method was evaluated.
**Results** Among 6,821 female patients with AS, 996 patients in the delivery group were younger, had a higher proportion of non-drug use, and had lower rates of comorbidity than the no delivery group. The alteration of prescriptions did not differ between the AS with delivery and the AS without delivery groups (OR 0.76, 95% CI 0.56–1.05). Furthermore, the overall alteration of prescriptions did not differ significantly between vaginal delivery (VD) and CS (OR 0.72, 95% CI 0.45–1.14).
**Conclusion** The rate of alteration of prescriptions was comparable between the AS patients with and without delivery. There was no association between VD and alteration of prescriptions compared with CS. Taken together, pregnancy and VD may not be assumed to be factors of AS worsening.
**Disclosure of Interests** None declared
DOI: 10.1136/annrheumdis-2019-eular.2519

## AB0725 ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION AND CARDIOVASCULAR RISK IN SPONDYLOARTHRITIS: DATA FROM COSPAR REGISTRY

Ladehesa Pineda Lourdes[1], Gómez García Ignacio[2], María del Carmen Castro Villegas[2], Pedro Seguí Azpilcueta[3],Maria del Carmen Abalos-Aguilera[4], Bautista Aguilar Laura[2], Inmaculada Concepcion Aranda-Valera[5], Rocio Segura[5],Rafaela Ortega Castro[5], Clementina López-Medina[6], Pérez Sánchez Laura[7], Puche Larrubia Maria Ángeles[5], Chary Lopez-Pedrera[4],Font Ugalde Pilar[5], Garrido Castro Juan Luis[6], Alejandro Escudero Contreras[5], Eduardo Collantes Estevez[5], Jiménez Gómez Yolanda[4], COSPAR Study Group. *[1]Universitary Hospital Reina Sofia, Rheumatology, Córdoba, Spain; [2]Reina Sofía University Hospital/IMIBIC/University of Cordoba, Rheumatology, Cordoba, Spain; [3]Reina Sofía University Hospital/IMIBIC/University of Cordoba, Radiology, Córdoba, Spain; [4]IMIBIC, Córdoba, Spain; [5]Reina Sofía University Hospital/IMIBIC/University of Cordoba, Rheumatology, Córdoba, Spain; [6]University of Córdoba, Córdoba, Spain; [7]Reina Sofía University Hospital/IMIBIC/University of Cordoba, Rheumaology, Córdoba, Spain*

**Background:** Studies suggest that radiographic damage is associated with cardiovascular (CV) risk in axial spondyloarthritis (axSpA). However, the relationship among disease characteristics directly related to structural damage and CV risk has not yet been fully clarified.
**Objectives:** To analyze the association of structural damage with the presence of atherosclerotic plaques via carotid ultrasound (US) and the increased CV risk in a registry of patients with SpA.
**Methods:** Eighty-five patients with SpA (ASAS criteria) from the SpA registry from Cordoba (CoSpaR) were selected for a cross-sectional study and underwent a complete clinical history, physical examination and biochemical analysis. Variables about demographics, clinical parameters and CV risk factors were collected. CV risk was evaluated by estimating SCORE index and assessing presence of atherosclerotic plaques through carotid US performed by a qualified radiologist. Independent-samples t test was used to evaluate the association between radiological characteristics and presence of atherosclerosis. Multiple lineal regression (MLR) was performed to assess the variables potentially associated with increased SCORE. All comparisons were bilateral.
**Results:** Baseline characteristics are shown in the table. Values are mean±SD for quantitative and N (%) for qualitative variables. Regarding characteristics related with radiographic damage and CV risk, they exhibited a mSASSS of 14.84±18.4 (7.27±9.64 in cervical spine and 7.72 ±10.14 in lumbar spine). Average BMI 26.88±4.13, 33 (38.8%) were smokers, 16 (18.8%) had diagnosis of arterial hypertension, 1 (1.2%) of diabetes mellitus, 13 (15.3%) of hyperlipidemia, and 8 (9.4%) took lipid lowering drugs. Examination with carotid US found that 14 (16.5%) patients had previously unknown atherosclerotic plaques. After classification according to SCORE index, 60 (76.9%) had low CV risk, 10 (12.8%) moderate, and both high and very high CV risk categories had 4 (5.1%) patients each.
In patients with atherosclerotic plaques, age, disease duration and variables related to radiographic damage (mSASSS [total, cervical and lumbar], and bone bridges) were significantly higher ($p<0.05$). In addition, mSASSS in cervical spine ($p=0.063$) and age ($p<0.001$) were associated with the SCORE and were predictors of increased CV risk in MLR analysis.

| | |
|---|---|
| Age (years) (N=85) | 44.5±12.2 |
| Sex (males) (N=85) | 59 (69.4) |
| HLA B27 (N=83) | 71 (83.5) |
| axSpA (N=85) | 79 (92.9) |
| Radiographic axSpA (N=77) | 63 (74.1) |
| BMI (kg/m$^2$) (N=80) | 26,9±4.13 |
| Disease duration (years) (N=82) | 18.01±13.62 |
| Smokers (N=84) | 33 (38.8) |
| ASDAS-CRP | 3.13±1.05 |
| ASAS HI (N=82) | 4.05±3.8 |

**Conclusion:** Presence of atherosclerosis is associated with age, disease duration and radiographic damage in SpA. Age and structural damage especially in the cervical spine predicted a greater CV risk. Thus, it is important to identify these patients in order to maintain tight control and avoid development of CV disease.
**Acknowledgement: Funded by: JA PI-0139-2017**
**Disclosure of Interests: Ladehesa Pineda Lourdes: None declared, Gómez García Ignacio: None declared, María del Carmen Castro Villegas Paid instructor for: MSD, Abbvie, Pfizer, Janssen, Lilly, Roche, Pedro Seguí Azpilcueta: None declared, Maria del Carmen Abalos-Aguilera: None declared, Bautista Aguilar Laura: None declared, Inmaculada Concepcion Aranda-Valera: None declared, Rocio Segura: None declared, Rafaela Ortega Castro: None declared, Clementina López-Medina: None declared, Pérez Sánchez Laura: None declared, Puche Larrubia Maria Ángeles: None declared, Chary Lopez-Pedrera: None declared, Font Ugalde Pilar: None declared, Garrido Castro Juan Luis: None declared, Alejandro Escudero Contreras: None declared, Eduardo Collantes Estevez: None declared, Jiménez Gómez Yolanda: None declared**
**DOI:** 10.1136/annrheumdis-2019-eular.6050

## AB0726 WHAT IS THE IMPACT OF MRI ON THE PERFORMANCE OF THE ASAS CLASSIFICATION CRITERIA IN PATIENTS PRESENTING WITH UNDIAGNOSED BACK PAIN?

[1,2]Walter P. Maksymowych, Raj Carmona[3], James Yeung[4], Jon Chan[5], Liam Martin[6], Sibel Aydin[7], Dianne Mosher[6], Ariel Masetto[8], Stephanie Keeling[1], Olga Ziouzina[6], Sherry Rohekar[9], Joel Paschke[2], Amanda Carapellucci[2], Robert G. Lambert[1]. *[1]University of Alberta, Edmonton, Canada; [2]CaRE Arthritis, Edmonton, Canada; [3]McMaster University, Hamilton, Canada; [4]James Yeung Rheumatology, Vancouver, Canada; [5]Artus Health Center, Vancouver, Canada; [6]University of Calgary, Calgary, Canada; [7]University of Ottawa, Ottawa, Canada; [8]University of Sherbrooke, Sherbrooke, Canada; [9]Lawson Health Research Institute, London, Canada*

**Background:** Several cohorts have reported the performance of the ASAS classification criteria in settings where clinical, radiographic, and MRI features have been simultaneously incorporated into the diagnostic evaluation in arriving at a gold standard for the testing of the criteria. MRI improves diagnostic precision but access is limited and it is therefore still important to understand how the criteria perform in a setting where diagnostic evaluation can be conducted sequentially before and after MRI assessment. We hypothesized that the ASAS criteria would demonstrate enhanced specificity when MRI is available due to enhanced diagnostic precision.

Ann Rheum Dis: first published as 10.1136/annrheumdis-2019-eular.5888 on 27 June 2019. Downloaded from http://ard.bmj.com/ on November 27, 2020 at Eskisehir Osmangazi University. Protected by copyright.